Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 101 to 125 of 2422

TitleReference numberPublishedLast updated
Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessmentHTE17
Ovarian cancer: identifying and managing familial and genetic riskNG241
Momelotinib for treating myelofibrosis-related splenomegaly or symptomsTA957
Suspected sepsis: recognition, diagnosis and early managementNG51
Neonatal infection: antibiotics for prevention and treatmentNG195
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and managementNG240
ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessmentHTE5
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19TA878
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedemaTA953
Dupilumab for treating moderate to severe prurigo nodularisTA955
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and overTA956
Lung cancer: diagnosis and managementNG122
Vitamin B12 deficiency in over 16s: diagnosis and managementNG239
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA954
Digital technologies for delivering multidisciplinary weight-management services: early value assessmentHTE14
Digital technologies for managing non-specific low back pain: early value assessmentHTE16
Endoscopic sleeve gastroplasty for obesityIPG783
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutationsTA952
TuberculosisNG33
Digitally enabled therapies for adults with depression: early value assessmentHTE8
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and overTA949
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and overTA950
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancerTA951
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatmentsTA947
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatmentsTA948

Results per page

  1. 10
  2. 25
  3. 50
  4. All